These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32145705)

  • 1. Effects of β2-Adrenergic Agonists on Risk of Parkinson's Disease in COPD: A Population-Based Study.
    Chen W; Sadatsafavi M; Tavakoli H; Samii A; Etminan M
    Pharmacotherapy; 2020 May; 40(5):408-415. PubMed ID: 32145705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta2-adrenoreceptor agonists and long-term risk of Parkinson's disease.
    Tuominen JA; Bjørnevik K; Romanowska J; Solheim MH; Grydeland TB; Cortese M; Scherzer CR; Riise T; Igland J
    Parkinsonism Relat Disord; 2023 May; 110():105389. PubMed ID: 37027994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. β2-adrenoceptor agonists and antagonists and risk of Parkinson's disease.
    Gronich N; Abernethy DR; Auriel E; Lavi I; Rennert G; Saliba W
    Mov Disord; 2018 Sep; 33(9):1465-1471. PubMed ID: 30311974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. β2-Adrenoceptor Agonists in Asthma or Chronic Obstructive Pulmonary Disease and Risk of Parkinson's Disease: Nested Case-Control Study.
    Paakinaho A; Tiihonen M; Koskela H; Koponen M; Tiihonen J; Hartikainen S; Tolppanen AM
    Clin Epidemiol; 2023; 15():695-705. PubMed ID: 37332323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β2-adrenoreceptor medications and risk of Parkinson disease.
    Searles Nielsen S; Gross A; Camacho-Soto A; Willis AW; Racette BA
    Ann Neurol; 2018 Nov; 84(5):683-693. PubMed ID: 30225948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between use of ß2-adrenergic receptor agonists and incidence of Parkinson's disease: Retrospective cohort analysis.
    Nadeem H; Zhou B; Goldman D; Romley J
    PLoS One; 2022; 17(11):e0276368. PubMed ID: 36441791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting.
    Perrone V; Sangiorgi D; Buda S; Degli Esposti L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2749-2755. PubMed ID: 27853362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. β 2-Agonists and the Incidence of Parkinson Disease.
    Giorgianni F; Ernst P; Dell'Aniello S; Suissa S; Renoux C
    Am J Epidemiol; 2020 Aug; 189(8):801-810. PubMed ID: 32016345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of β2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease.
    Hopfner F; Wod M; Höglinger GU; Blaabjerg M; Rösler TW; Kuhlenbäumer G; Christensen K; Deuschl G; Pottegård A
    Neurology; 2019 Jul; 93(2):e135-e142. PubMed ID: 31127070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. β
    Arif E; Medunjanin D; Solanki A; Zuo X; Su Y; Dang Y; Winkler B; Lerner K; Kamal AI; Palygin O; Cornier MA; Wolf BJ; Hunt KJ; Lipschutz JH
    Am J Physiol Renal Physiol; 2024 Jan; 326(1):F20-F29. PubMed ID: 37916289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease.
    Zeng LH; Hu YX; Liu L; Zhang M; Cui H
    Clin Interv Aging; 2013; 8():1157-65. PubMed ID: 24072964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Role of β2-Adrenoreceptor Agonists Related to the Development of Parkinson's Disease.
    Jung D; Kwak DW; Kim M; Lee WW
    Neurol India; 2023; 71(4):710-715. PubMed ID: 37635503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of inhaled corticosteroids in monotherapy or combined with long-acting {beta}2-agonists on mortality among patients with chronic obstructive pulmonary disease.
    Cyr MC; Beauchesne MF; Lemière C; Aaron SD; Blais L
    Ann Pharmacother; 2010 Apr; 44(4):613-22. PubMed ID: 20233915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association between chronic obstructive pulmonary disease and Parkinson's disease: a nationwide population-based retrospective cohort study.
    Li CH; Chen WC; Liao WC; Tu CY; Lin CL; Sung FC; Chen CH; Hsu WH
    QJM; 2015 Jan; 108(1):39-45. PubMed ID: 25024356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhaled Pharmacotherapy and Stroke Risk in Patients with Chronic Obstructive Pulmonary Disease: A Nationwide Population Based Study Using Two-Stage Approach.
    Lin HW; Chung CL; Lin YS; Yu CM; Lee CN; Bien MY
    PLoS One; 2015; 10(7):e0130102. PubMed ID: 26158649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction in Hospital Readmission Rates Among Medicare Beneficiaries With Chronic Obstructive Pulmonary Disease: A Real-world Outcomes Study of Nebulized Bronchodilators.
    Keshishian A; Xie L; Dembek C; Yuce H
    Clin Ther; 2019 Nov; 41(11):2283-2296. PubMed ID: 31630815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated blood lactate in COPD exacerbations associates with adverse clinical outcomes and signals excessive treatment with β
    MacDonald MI; Polkinghorne KR; MacDonald CJ; Leong P; Hamza K; Kathriachchige G; Osadnik CR; King PT; Bardin PG
    Respirology; 2023 Sep; 28(9):860-868. PubMed ID: 37400102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study.
    Moretz C; Sharpsten L; Bengtson LG; Koep E; Le L; Tong J; Stanford RH; Hahn B; Ray R
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1721-1737. PubMed ID: 31534326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Effectiveness of Long-Acting Beta
    Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
    Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy of inhaled steroids and long-acting beta2-agonists in asthma-COPD overlap syndrome.
    Lee SY; Park HY; Kim EK; Lim SY; Rhee CK; Hwang YI; Oh YM; Lee SD; Park YB
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2797-2803. PubMed ID: 27877033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.